See more : Alerio Gold Corp. (ALE.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Human Metabolome Technologies, Inc. (6090.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Human Metabolome Technologies, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Virat Crane Industries Limited (VIRATCRA.BO) Income Statement Analysis – Financial Results
- DEUTZ Aktiengesellschaft (DEUZF) Income Statement Analysis – Financial Results
- PT Bank Amar Indonesia Tbk (AMAR.JK) Income Statement Analysis – Financial Results
- MEDirect Latino, Inc. (MLTO) Income Statement Analysis – Financial Results
- Paragon ID SA (PAGDF) Income Statement Analysis – Financial Results
Human Metabolome Technologies, Inc. (6090.T)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.humanmetabolome.com
About Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.35B | 1.30B | 1.22B | 1.12B | 1.12B |
| Cost of Revenue | 476.34M | 439.47M | 383.28M | 318.05M | 261.77M |
| Gross Profit | 869.33M | 859.75M | 840.01M | 806.02M | 856.72M |
| Gross Profit Ratio | 64.60% | 66.17% | 68.67% | 71.71% | 76.60% |
| Research & Development | 181.49M | 185.00M | 158.00M | 98.00M | 155.00M |
| General & Administrative | 61.00M | 59.00M | 55.00M | 59.00M | 60.00M |
| Selling & Marketing | 398.00M | 395.00M | 431.00M | 604.00M | 658.00M |
| SG&A | 457.91M | 454.00M | 486.00M | 663.00M | 718.00M |
| Other Expenses | 0.00 | 19.77M | 18.04M | 16.67M | 2.16M |
| Operating Expenses | 649.16M | 648.77M | 648.85M | 766.65M | 873.76M |
| Cost & Expenses | 1.13B | 1.09B | 1.03B | 1.08B | 1.14B |
| Interest Income | 14.00K | 14.00K | 11.00K | 125.00K | 81.00K |
| Interest Expense | 2.10M | 2.27M | 2.21M | 1.54M | 420.00K |
| Depreciation & Amortization | 86.32M | 80.39M | 64.90M | 55.85M | 47.97M |
| EBITDA | 350.31M | 319.65M | 329.02M | 108.33M | 23.84M |
| EBITDA Ratio | 26.03% | 24.27% | 26.17% | 10.40% | 3.04% |
| Operating Income | 220.17M | 210.98M | 191.15M | 39.37M | -17.04M |
| Operating Income Ratio | 16.36% | 16.24% | 15.63% | 3.50% | -1.52% |
| Total Other Income/Expenses | 41.74M | 26.02M | 70.76M | 11.58M | -7.50M |
| Income Before Tax | 261.90M | 237.00M | 261.91M | 50.95M | -24.54M |
| Income Before Tax Ratio | 19.46% | 18.24% | 21.41% | 4.53% | -2.19% |
| Income Tax Expense | 18.65M | -48.76M | -5.87M | -7.26M | 23.25M |
| Net Income | 243.25M | 285.76M | 267.79M | 58.21M | -47.79M |
| Net Income Ratio | 18.08% | 21.99% | 21.89% | 5.18% | -4.27% |
| EPS | 41.14 | 48.39 | 45.39 | 9.87 | -8.15 |
| EPS Diluted | 41.14 | 48.39 | 45.39 | 9.86 | -8.15 |
| Weighted Avg Shares Out | 5.91M | 5.90M | 5.90M | 5.90M | 5.86M |
| Weighted Avg Shares Out (Dil) | 5.91M | 5.90M | 5.90M | 5.90M | 5.86M |
Source: https://incomestatements.info
Category: Stock Reports